Trial Profile
Phase II Randomized Double Blind Clinical Trial of Imatinib Mesylate STI571 (Glivec) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2014
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Scleroderma; Systemic scleroderma
- Focus Therapeutic Use
- Acronyms SCLEROGLIVEC
- 09 May 2014 New trial record
- 03 Mar 2011
- 23 Jan 2008